Method for improving affinity of antibody to antigen and use thereof
By adjusting the amino acid frequency and charge properties in the light chain framework region of the antibody, the affinity of the antibody is improved, the problem of improving the antibody affinity in the prior art is solved, and the significant enhancement of antigen binding ability is achieved.
Patent Information
- Application Number
- CN202411148111.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-05-28
- Filing Date
- 2020-12-18
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to significantly enhance the affinity of an antibody to antigen by changing its amino acid sequence, especially without changing the complementarity determination region (CDR).
In the light chain framework region (FR) of the antibody, the total amino acid frequency of arginine, serine, threonine, valine and aspartic acid is reached more than 35%, and at least 3 amino acid residues are added The group is set as a charged amino acid residue to enhance the affinity of the antibody.
A significant improvement in antigen affinity was achieved, and the binding ability of the antibody to the antigen was enhanced by changing the amino acid residues in the light chain framework region of the antibody.
Smart Images

Figure CN119019561A_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent application 202080070223.9 of the same name filed on December 18, 2020. [Technical field]
[0002] The present invention relates to a method for improving the affinity of an antibody for an antigen. The present invention relates to a modified antibody having an improved affinity for an antigen compared to an unmodified antibody. The present invention relates to a method for producing an antibody having an improved affinity for an antigen compared to an unmodified antibody. The present invention relates to a method for analyzing the amino acid sequence of an antibody. The present invention relates to a method for specifying candidate alteration positions of an antibody. [Background technology]
[0003] In the past, it is known that the affinity of an antibody for an antigen is changed by changing the amino acid sequence of the antibody. For example, Patent Document 1 describes a method for controlling the affinity for an antigen by setting at least three amino acid residues in the framework region 3 of an antibody to charged amino acid residues. In this method, the affinity of the antibody for the antigen is improved while maintaining the amino acid sequence of the complementarity determining region (CDR).
[0004] [Prior art literature]
[0005] [Patent Literature]
[0006] Patent Document 1: U.S. Patent Application Publication No. 2018 / 0179298
[0007] [Summary of the Invention]
[0008] [Problems to be solved by the invention]
[0009] The present invention aims to provide a new method for improving the affinity of an antibody for an antigen by changing the amino acid residues in the framework region (FR) without changing the amino acid sequence of the CDR, and a new antibody with improved affinity for the antigen.
[0010]
Methods for solving the problem
[0011] The present inventors have discovered that the total value of the amino acid frequency of a specified amino acid residue at each position in the amino acid sequence of FR of an antibody light chain and the surface area ratio of each amino acid residue in the FR exposed to the solvent are correlated with the affinity of the antibody for the antigen, thereby completing the present invention.
[0012] The present invention provides a method for improving the affinity of an antibody for an antigen compared to an unmodified antibody, comprising: in the amino acid sequence of the FR of the light chain of the antibody, setting at least three of the amino acid residues located at positions where the total value of the amino acid frequency of arginine, serine, threonine, valine, aspartic acid and glutamic acid is greater than 35% and where the solvent exposed surface area ratio shows a greater than 20% as charged amino acid residues.
[0013] The present invention provides a modified antibody having an improved affinity for an antigen compared to an unmodified antibody. In the modified antibody, in the amino acid sequence of the FR of the light chain of the unmodified antibody, at least three of the amino acid residues located at positions where the total value of the amino acid frequency of arginine, serine, threonine, valine, aspartic acid, and glutamic acid is 35% or more and where the solvent exposed surface area ratio is 20% or more are charged amino acid residues.
[0014] The present invention provides a method for producing an antibody having improved affinity for an antigen compared to an unmodified antibody, comprising: a step of setting, in the amino acid sequence of the FR of the light chain of the antibody, at least three of the amino acid residues located at a position where the total value of the amino acid frequency of arginine, serine, threonine, valine, aspartic acid and glutamic acid is 35% or more and where the solvent exposed surface area ratio is 20% or more as charged amino acid residues, and a step of recovering the antibody obtained in this step.
[0015] The present invention provides a method for analyzing the amino acid sequence of an antibody, which comprises: a step of obtaining a total value of the amino acid frequency of arginine, serine, threonine, valine, aspartic acid and glutamic acid at each position in the amino acid sequence of the FR of the light chain of the antibody, a step of obtaining the solvent-exposed surface area ratio of each amino acid residue in the framework region of the light chain of the antibody, and a step of outputting the obtained total value of the amino acid frequency at each position and the solvent-exposed surface area ratio of each amino acid residue.
[0016] The present invention provides a method for determining candidate change positions of an antibody, comprising: a step of obtaining a total value of the amino acid frequencies of arginine, serine, threonine, valine, aspartic acid and glutamic acid at each position in the amino acid sequence of the FR of the light chain of the antibody, a step of obtaining the solvent-exposed surface area ratio of each amino acid residue in the framework region of the light chain of the antibody, and a step of determining an amino acid residue located at a position where the total value of the amino acid frequency is 35% or more and the solvent-exposed surface area ratio shows 20% or more as a candidate amino acid residue to be changed in order to improve the affinity of the antibody for the antigen.
[0017] The present invention provides a modified antibody having an improved affinity for an antigen compared to an unmodified antibody. In the modified antibody, the positions of the modified amino acid residues are at least three positions of the candidate amino acid residues determined by the method for determining the candidate positions of the antibody, and the modification is a modification to a charged amino acid residue.
[0018] The present invention provides a method for producing an antibody with improved affinity for an antigen compared to an unmodified antibody, comprising: a step of setting at least three of the candidate amino acid residues determined by a method for determining candidate change positions of the antibody as charged amino acid residues, and a step of recovering the antibody obtained in this step.
[0019] The present invention provides a method for improving the affinity of an antibody for an antigen, comprising: in an unmodified antibody, at least three amino acid residues selected from amino acid residues 3, 5, 9, 17, 18, 20, 22, 60, 63, 65, 67, 70, 72, 74, 76, 77, 79 and 81 of a light chain as defined by the Kabat method are set as charged amino acid residues, thereby improving the affinity for the antigen compared to the unmodified antibody, wherein the three amino acid residues include at least one selected from amino acid residues 3, 5, 9, 17, 18, 20, 22, 60, 74, 76, 77, 79 and 81 of the light chain.
[0020] The present invention provides a modified antibody having an improved affinity for an antigen compared to an unmodified antibody. In the modified antibody, at least three amino acid residues selected from amino acid residues 3, 5, 9, 17, 18, 20, 22, 60, 63, 65, 67, 70, 72, 74, 76, 77, 79 and 81 of the light chain defined by the Kabat method in the unmodified antibody are set as charged amino acid residues, and the three amino acid residues include at least one selected from amino acid residues 3, 5, 9, 17, 18, 20, 22, 60, 74, 76, 77, 79 and 81 of the light chain.
[0021] The present invention provides a method for producing an antibody having improved affinity for an antigen compared to an unmodified antibody, comprising: a step of setting at least three amino acid residues selected from amino acid residues 3, 5, 9, 17, 18, 20, 22, 60, 63, 65, 67, 70, 72, 74, 76, 77, 79 and 81 of a light chain defined by the Kabat method as charged amino acid residues in the unmodified antibody, and a step of recovering the antibody obtained in this step, wherein the three amino acid residues include at least one selected from amino acid residues 3, 5, 9, 17, 18, 20, 22, 60, 74, 76, 77, 79 and 81 of the light chain.
[0022] [Effects of the invention]
[0023] According to the present invention, an antibody having improved affinity for an antigen is provided.
[0024] [Brief description of the attached drawings]
[0025]
Figure 1
[0026]
Figure 2
[0027]
Figure 3
[0028]
Figure 4
[0029]
Figure 5
[0030]
Figure 6
[0031]
Figure 7
[0032]
Figure 8
[0033]
Fig. 9
[0034] [1. Method for improving the affinity of antibodies for antigens]
[0035] In the method for improving the affinity of an antibody for an antigen of the present embodiment (hereinafter also referred to as "the affinity improvement method"), at least three amino acid residues are set as charged amino acid residues among the amino acid residues that meet the specified conditions in the amino acid sequence of the FR of the light chain of the antibody. As a result, the affinity of the antibody for the antigen is improved compared to the unmodified antibody. Among them, the original antibody whose affinity for the antigen is improved by the method provided by the present invention is referred to as an "unmodified antibody". In this specification, "unmodified antibody" refers to an antibody having an amino acid sequence before the "affinity improvement method" is applied. "Unmodified antibody" is not only an antibody having a natural amino acid sequence (wild-type antibody), but also an antibody whose amino acid sequence is artificially changed based on methods other than the "affinity improvement method".
[0036] In the present embodiment, the unchanged antibody is not particularly limited. The affinity enhancement method of the present embodiment can also be an antibody that recognizes any antigen because there is no need to change the amino acid sequence of CDR. In a preferred embodiment, the unchanged antibody is an antibody whose base sequence of the gene encoding the variable region of the light chain is known or can confirm the base sequence. Specifically, an antibody whose base sequence of the antibody gene is disclosed in a known database, or a hybridoma producing the antibody is an available antibody. As such a database, for example, GeneBank, abYsis, IMGT, etc. can be cited. Although the class of the antibody can be any one of IgG, IgA, IgM, IgD and IgE, IgG is preferably used. As long as the unchanged antibody has a variable region containing FR, it can also be in the form of an antibody fragment. As such an antibody fragment, for example, Fab fragment, F(ab')2 fragment, Fab' fragment, Fd fragment, Fv fragment, dAb fragment, single-chain antibody (scFv), reduced IgG (rIgG), etc. can be cited. Among them, Fab fragment is also particularly preferred.
[0037] As an example of an unmodified antibody, the amino acid sequences of the light chain and heavy chain of a humanized anti-HER2 antibody (trastuzumab), and the amino acid sequence of the heavy chain of a Fab fragment are shown in Table 1. In Table 1, the underlined portion indicates the variable region, and the portion marked in gray indicates the CDR.
[0038]
Table 1
[0039]
[0040] The amino acid sequences of each CDR and variable region of the light chain of the wild-type humanized anti-HER2 antibody are as follows.
[0041] Light chain CDR1: RASQDVNTAV A (SEQ ID NO: 38)
[0042] Light chain CDR2: SASFLYS (SEQ ID NO: 39)
[0043] Light chain CDR3: QQHYTTPPT (SEQ ID NO: 40)
[0044] ·Variable area: DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYSASFLYSGVPS RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV(SEQ ID NO:41)
[0045] The amino acid sequences of each CDR and variable region of the heavy chain of the wild-type humanized anti-HER2 antibody are as follows.
[0046] Heavy chain CDR1: DTYIH (SEQ ID NO: 42)
[0047] Heavy chain CDR2: RIYPTNGYTR YADSVKG (SEQ ID NO: 43)
[0048] Heavy chain CDR3: WGGDGFYAMD Y (SEQ ID NO: 44)
[0049] ·Variable region: EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVARIYPTNGYTRY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS(SEQ ID NO:45)
[0050] Framework region (FR) refers to the region outside the CDR of each variable region of the light chain and heavy chain of an antibody. FR plays the role of a scaffold connecting three CDRs, and contributes to the structural stability of CDR. Therefore, the amino acid sequence of FR is highly conserved between antibodies of the same species. In each variable region of the light chain and heavy chain, there are three CDRs of CDR1, CDR2 and CDR3 and four FRs of FR1, FR2, FR3 and FR4. These are arranged in the order of FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 from the N-terminal side of the variable region. Hereinafter, when referring to the FR of an antibody, when there is no special explanation, the terms "framework region" and "FR" refer to the FR of the light chain.
[0051] In the affinity enhancement method of the present embodiment, at least three of the amino acid residues that satisfy the specified conditions in the amino acid sequence of the FR of the light chain of the unchanged antibody are set as charged amino acid residues. The amino acid residues that satisfy the specified conditions refer to amino acid residues that satisfy both the following conditions (1) and (2).
[0052] (1) A position at which the total value of the amino acid frequencies of arginine, serine, threonine, valine, aspartic acid, and glutamic acid is 35% or more in the amino acid sequence of the FR of the light chain of the unmodified antibody.
[0053] (2) In the amino acid sequence of the FR of the light chain of the unchanged antibody, the surface area ratio exposed to the solvent is 20% or more.
[0054] In this specification, the amino acid residues satisfying the above-mentioned conditions (1) and (2) in the unmodified antibody are also referred to as "modification" or "alteration". Hereinafter, the antibody obtained by modifying the unmodified antibody by the affinity enhancement method of this embodiment is also referred to as "modified antibody".
[0055] Since CDR is related to the specificity of the antibody, in the affinity enhancement method of this embodiment, it is preferred not to change the amino acid sequence of CDR. In other words, the amino acid sequence of the modified antibody CDR is preferably the same as the amino acid sequence of the unmodified antibody CDR.
[0056] In this embodiment, the affinity of the antibody for the antigen can be evaluated by the kinetic parameters in the antigen-antibody reaction, or by immunological assays such as ELISA. Examples of kinetic parameters include the dissociation constant (K d ), binding rate constant (k on ) and dissociation rate constant (k off ). Among them, K is also preferred. d The kinetic parameters in the antigen-antibody reaction can be obtained by surface plasmon resonance (SPR) technology. d The value is, for example, about 1 / 2, about 1 / 5, about 1 / 10, about 1 / 20, about 1 / 50, about 1 / 100, or about 1 / 1000 compared to the unaltered antibody.
[0057] In this specification, "position" refers to the position of an amino acid residue in a certain amino acid sequence. In the present embodiment, the position in the amino acid sequence of FR is the position in the amino acid sequence of FR defined by the method for numbering the amino acid residues of CDR (hereinafter, also referred to as "numbering method"). The numbering method is a method for defining the boundaries and lengths of CDR, which is well known in the prior art. Numbers are attached to the amino acid residues of CDR by the numbering method, and the amino acid residues of FR will also be attached with numbers. In the present embodiment, the position in the amino acid sequence of FR is represented by the numbering method attached. In the present specification, "Ln" (n is a positive integer) represents the nth position in the light chain amino acid sequence. For example, L1 refers to the 1st position of the light chain amino acid sequence, and L2 refers to the 2nd position of the light chain amino acid sequence.
[0058] Examples of the numbering method include the Kabat method (Kabat EA. et al., Sequences of Proteins of Immunological Interest., NIH publication No. 91-3242), the Chothia method (Chothia C. and Lesk AM., Canonical Structures for the Hypervariable Regions of Immunoglobulins., J Mol Biol., vol. 196, p. 901-917, 1987), the IMGT method (Lefranc MP. et al., Developmental and Comparative Immunology 29 (2005) 185-203), the Honegger method (Honegger A. et al., Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modeling and Analysis Tool., J Mol Biol., vol. 309, p. 657-670, 2001), the ABM method, and the Contact method. In this embodiment, the FR of the antibody may be defined by any numbering method, but is preferably defined by the Kabat method. In an unmodified antibody, in the Kabat method, the FR1 of the light chain is defined as a region consisting of the 1st to 23rd amino acid residues of the light chain, the FR2 of the light chain is defined as a region consisting of the 35th to 49th amino acid residues of the light chain, the FR3 of the light chain is defined as a region consisting of the 57th to 88th amino acid residues of the light chain, and the FR4 of the light chain is defined as a region consisting of the 98th to 109th amino acid residues of the light chain.
[0059] Amino acid frequency is also called amino acid occurrence frequency, which refers to the comparison of multiple amino acid sequences to show the ratio of the degree to which the specified amino acid appears at each position of these amino acid sequences. Amino acid frequency itself is a well-known index. The comparison of amino acid sequences refers to the alignment of multiple amino acid sequences. The comparison of amino acid sequences can be performed by known multiple comparison programs such as ClustalW and TREBMAL. In addition, the calculation method of amino acid frequency itself is well known and can be calculated by the above-mentioned multiple comparison programs. The comparison of amino acid sequences and the calculation of amino acid frequency can also be performed by abYsis. abYsis can be used not only as a database for providing antibody sequences, but also as software for analyzing and predicting antibody sequences, structures and functions. For example, at the specified position of the multiple amino acid sequences compared, when a certain amino acid appears in all of the multiple amino acid sequences, the amino acid frequency of the amino acid at the position becomes 100%. At the specified position of the multiple amino acid sequences compared, when a certain amino acid appears in half of the multiple amino acid sequences, the amino acid frequency of the amino acid at the position becomes 50%. When a certain amino acid does not appear even once at a given position in a plurality of aligned amino acid sequences, the amino acid frequency of the amino acid at that position becomes 0%.
[0060] In this embodiment, in order to determine the amino acid residues that satisfy the above-mentioned condition (1) in the FR of the unmodified antibody, the amino acid sequences of the light chains of multiple reference antibodies are obtained. By comparing the amino acid sequences of the light chains of the multiple reference antibodies obtained, the amino acid frequencies of each position in the amino acid sequence of the FR of the light chain of the reference antibody can be obtained. The amino acid frequencies of each position obtained from the multiple reference antibodies can be used as the amino acid frequencies of the corresponding positions in the amino acid sequence of the light chain of the unmodified antibody. The reference antibody is not particularly limited as long as it is an antibody different from the amino acid sequence of the unmodified antibody. Since the amino acid sequence of the FR of the antibody is highly conserved between antibodies of the same species, the reference antibody is preferably an antibody of the same species as the unmodified antibody. The amino acid sequence of the light chain of the reference antibody can be obtained from known databases such as GeneBank, abYsis, IMGT, etc. The number of amino acid sequences of the light chain of the reference antibody is not particularly limited, for example, more than 1000, preferably more than 10000. The amino acid sequences of the light chains of the multiple reference antibodies obtained can be the amino acid sequence of the entire light chain, or the amino acid sequence of a part of the light chain. The amino acid sequence of a part of the light chain preferably contains the amino acid sequence of FR1 and / or FR3.
[0061] The amino acid sequences of the light chains of the multiple reference antibodies obtained are compared to obtain the respective amino acid frequencies of arginine (R), serine (S), threonine (T), valine (V), aspartic acid (D) and glutamic acid (E) at each position of the amino acid sequence of the FR of the reference antibody. Wherein, "comparing the amino acid sequences of the light chains of multiple reference antibodies" refers to aligning the amino acid sequences of the light chains of the multiple reference antibodies in a manner consistent with the numbering of the amino acid residues in the FR attached by the specified numbering method. In the present embodiment, it is preferred to align the amino acid sequences of the light chains of the multiple reference antibodies in a manner consistent with the numbering of the amino acid residues in the FR attached by the Kabat method. For each position, the values of the amino acid frequencies of R, S, T, V, D and E are totaled to calculate the total value. For example, the total value X (%) of the amino acid frequency at a certain position in the amino acid sequence of the light chain of multiple reference antibodies for comparison can be calculated from the number of R, S, T, V, D and E appearing at the said position and the number of amino acid sequences of the light chain of the reference antibody obtained by the following formula (I). This calculation is performed for each position of the amino acid sequence of FR1 of the light chain and / or FR3 of the light chain of multiple reference antibodies for comparison. The number of amino acid sequences of the light chain of the reference antibody used in the calculation may also be different for each position. For example, the value of X in L1 can also be calculated based on the amino acid sequences of the light chains of 10,000 reference antibodies, and the value of X in L2 can also be calculated based on the amino acid sequences of the light chains of 15,000 reference antibodies.
[0062]
Number 1
[0063] X=(((the number of R's)+(the number of S's)+(the number of T's)+(the number of V's)+(the number of D's)+(the number of E's)) / (the number of amino acid sequences of the light chain of the reference antibody))×100……(I)
[0064] In the amino acid sequences of the light chains of the multiple reference antibodies being compared, the positions at which the total value of the amino acid frequencies obtained is 35% or more, preferably 37% or more are determined. Furthermore, as the amino acid residues satisfying the condition of (1) above, the amino acid residues at the positions corresponding to the positions determined from the multiple reference antibodies in the FR of the light chain of the unmodified antibody are determined. Such amino acid residues can also be determined by, for example, comparing the amino acid sequence of the light chain of the unmodified antibody with the amino acid sequences of the light chains of the multiple reference antibodies. When the amino acid sequences of the light chains of the multiple reference antibodies are compared based on, for example, the FR defined by the Kabat method, in the FR of the unmodified antibody, the amino acid residues whose numbers assigned by the Kabat method are the same as the positions in the sequences of the reference antibodies at which the total value of the amino acid frequencies is 35% or more are determined.
[0065] In the present embodiment, the amino acid residues satisfying the condition of (2) above are determined based on the amino acid sequence of the light chain of the unchanged antibody. Specifically, first, the amino acid sequence of the light chain of the unchanged antibody is used to obtain the three-dimensional structural data of the light chain of the unchanged antibody. The three-dimensional structural data preferably may contain the coordinate data of each amino acid residue constituting the protein, and the data of the three-dimensional structure of the protein is visualized by the known molecular graphics programs such as RasMol and Jmol. The three-dimensional structural data can also be obtained by performing known three-dimensional structural analysis such as X-ray crystallographic structure analysis and NMR analysis for the light chain of the unchanged antibody. In a preferred embodiment, the three-dimensional structural data is retrieved from the known protein three-dimensional structure databases such as PDB (Protein Data Bank) and BMRB (Biological Magnetic Resonance Bank) to start with the amino acid sequence of the light chain of the unchanged antibody. When there is a protein having a sequence consistent with the amino acid sequence of the light chain of the unchanged antibody, the three-dimensional structural data of the protein is downloaded from the database.
[0066] When there is no three-dimensional structural data of the light chain of the unmodified antibody in the protein three-dimensional structure database, the information necessary for the preparation of the three-dimensional structural data can also be obtained, and the three-dimensional structural data can be prepared based on the information. For example, the three-dimensional structural data can also be prepared by homology modeling based on the amino acid sequence of the light chain of the unmodified antibody. In the homology modeling method, as the necessary information for the preparation of the three-dimensional structural data, the amino acid sequence of the light chain of the unmodified antibody with at least 20% homology and the amino acid sequence of the light chain of the antibody with known three-dimensional structure (hereinafter also referred to as "reference sequence") is used. It is known in the prior art that the three-dimensional structures are similar to each other between proteins with high homology of amino acid sequences. The reference sequence can be obtained, for example, from the known databases of GeneBank, abYsis, IMGT, etc. In the homology modeling method, the amino acid sequence of the light chain of the unmodified antibody and the reference sequence are compared, and the three-dimensional structure of the light chain of the unmodified antibody is constructed from the known structure of the reference sequence based on the result of the comparison. The preparation of three-dimensional structural data by homology modeling is known per se and can be performed by, for example, a known three-dimensional structure prediction program such as MODELLER.
[0067] Next, the surface area ratio of each amino acid residue of the FR of the unchanged antibody exposed to the solvent is obtained based on the obtained three-dimensional structural data. In the prior art, the surface area exposed to the solvent is defined as the surface area of the probe ball of the putative water molecule rotating in contact with the surface (van der Waals surface) of the protein molecule. The trajectory surface of the center of the probe ball at that time. The surface area exposed to the solvent itself is a well-known indicator. The surface area of a protein exposed to the solvent can be obtained from the three-dimensional structural data of the protein by well-known programs or software such as SURFace, GETAREA, Discovery Studio, etc. In addition, the surface area of each amino acid residue in the protein exposed to the solvent can also be obtained. The surface area of an amino acid residue in a protein exposed to the solvent varies depending on the size of the side chain of the amino acid. Therefore, as an indicator for normalizing the surface area of an amino acid residue in a protein exposed to the solvent by the size of the side chain of the amino acid, the surface area ratio exposed to the solvent is used. The surface area ratio exposed to the solvent itself is a well-known indicator. For example, the surface area ratio Y (%) of an amino acid X in a protein A exposed to the solvent is calculated by the following formula (II). In the formula, "Ala-X-Ala" refers to a tripeptide consisting of a sequence in which the amino acid X is sandwiched by two alanines.
[0068]
Number 2
[0069] Y = ((surface area of amino acid X in protein A exposed to solvent) / (surface area of amino acid X in Ala-X-Ala exposed to solvent)) × 100 ... (II)
[0070] Furthermore, in the amino acid sequence of the FR of the unmodified antibody, an amino acid residue having a surface area ratio exposed to the solvent of 20% or more, preferably 25% or more is identified. Thus, in the amino acid sequence of the FR of the unmodified antibody, an amino acid residue at a position where the total value of the amino acid frequency of R, S, T, V, D and E is 35% or more and which has a surface area ratio exposed to the solvent of 20% or more can be identified.
[0071] Among the amino acid residues satisfying the conditions of (1) and (2) above, the number of amino acid residues set as charged amino acid residues is, for example, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18. The charged amino acid residues may be basic amino acid residues or acidic amino acid residues. Preferably, the charged amino acid residues are amino acid residues of the same charge. The charged amino acid residues may be the same residues or different residues. Basic amino acid residues refer to lysine residues, arginine residues and histidine residues. Acidic amino acid residues refer to aspartic acid residues and glutamic acid residues. In the present embodiment, as the charged amino acid residues, basic amino acid residues are preferred, and lysine residues and arginine residues are particularly preferred.
[0072] Among the amino acid residues satisfying the conditions of (1) and (2) above, the amino acid residue used as the charged amino acid residue is preferably a neutral amino acid residue. Neutral amino acid residues refer to alanine residues, asparagine residues, isoleucine residues, glycine residues, glutamine residues, cysteine residues, threonine residues, serine residues, tyrosine residues, phenylalanine residues, proline residues, valine residues, methionine residues, leucine residues and tryptophan residues.
[0073] When the amino acid residue satisfying the above conditions (1) and (2) is a charged amino acid residue, the amino acid residue may be left unchanged. Alternatively, when the amino acid residue satisfying the above conditions (1) and (2) is an acidic amino acid residue, the amino acid residue may be set to a basic amino acid residue. In addition, when the amino acid residue satisfying the above conditions (1) and (2) is a basic amino acid residue, the amino acid residue may be set to an acidic amino acid residue.
[0074] In this embodiment, when the electrical properties of the CDR based on the amino acid sequence of the CDR of the unchanged antibody are neutral, the amino acid residues satisfying the above-mentioned conditions (1) and (2) may also be set as charged amino acid residues. The charged amino acid residues are preferably basic amino acid residues. Among them, the electrical properties of the CDR refer to indicators independently defined by the inventors, which are determined based on the number of charged amino acid residues in the amino acid sequence of the CDR. Specifically, the electrical properties of the CDR are determined by the following formula (III).
[0075] Z = [the number of basic amino acid residues in the amino acid sequence of CDR] - [the number of acidic amino acid residues in the amino acid sequence of CDR] (III)
[0076] (Where Z is -1, 0 or 1, the electrical properties of the CDR are neutral,
[0077] When Z is 2 or more, the electrical characteristic of CDR is positive charge.
[0078] When Z is below -2, the electrical characteristic of CDR is negative charge)
[0079] The electrical properties of CDR can also be determined based on the amino acid sequence of the CDR of the light chain and / or heavy chain. When determining the electrical properties of the CDR of the light chain, the amino acid sequence of the CDR in formula (III) refers to the entire amino acid sequence of CDR1, CDR2 and CDR3 of the light chain. In addition, when determining the electrical properties of the CDR of the heavy chain, the amino acid sequence of the CDR in formula (III) refers to the entire amino acid sequence of CDR1, CDR2 and CDR3 of the heavy chain. It is preferably determined based on the amino acid sequence of the CDR of both the light chain and the heavy chain. At this time, the amino acid sequence of the CDR in the above-mentioned formula (III) refers to the entire amino acid sequence of CDR1, CDR2 and CDR3 of the light chain and CDR1, CDR2 and CDR3 of the heavy chain. In the present embodiment, in the unaltered antibody whose electrical properties determined based on the amino acid sequence of the CDR of both the light chain and the heavy chain are neutral, at least 3 of the amino acid residues that meet the conditions of (1) and (2) above can also be set to charged amino acid residues, preferably basic amino acid residues.
[0080] The amino acid sequence of CDR can be obtained from a public database that discloses the sequence of antibody genes. Alternatively, when there is a hybridoma that produces an unmodified antibody, the amino acid sequence of CDR can be obtained by obtaining a nucleic acid encoding a heavy chain and a light chain from the hybridoma by a known method and sequencing the base sequence of the nucleic acid.
[0081] The electrical properties of CDR vary depending on the antibody. For example, in the Kabat method, in the CDR of the light chain of the wild-type (i.e., unchanged) anti-lysozyme antibody used in the examples described below, there is one basic amino acid residue (arginine) and no acidic amino acid residue. In addition, in the CDR of the heavy chain, there is one basic amino acid residue (lysine) and three acidic amino acid residues (aspartic acid). Thus, the electrical properties of the CDR of the wild-type anti-lysozyme antibody are defined as neutral (Z=-1). Furthermore, the electrical properties of the CDR of the anti-lysozyme antibody based on the Chothia method become negative charges.
[0082] The amino acid residue satisfying the conditions of (1) and (2) above is preferably an amino acid residue in FR1 and / or FR3. As the amino acid residue satisfying the conditions of (1) and (2) above in FR1 and FR3 of the light chain, for example, the 1st, 3rd, 5th, 7th, 9th, 10th, 12th, 14th, 17th, 18th, 20th, 22nd, 60th, 63rd, 65th, 67th, 69th, 70th, 72nd, 74th, 76th, 77th, 79th and 81st amino acid residue of the light chain defined by the Kabat method can be enumerated. Among these, the 1st, 3rd, 5th, 7, 9th, 10th, 12th, 14th, 17th, 18th, 20th and 22nd amino acid residue are in the FR1 of the light chain defined by the Kabat method, and the 60th, 63rd, 65th, 67th, 69th, 70th, 72nd, 74th, 76th, 77th, 79th and 81st amino acid residue are in the FR3 of the light chain defined by the Kabat method.
[0083] In a preferred embodiment, the amino acid residues satisfying the conditions of (1) and (2) above are amino acid residues 3, 5, 9, 17, 18, 20, 22, 60, 63, 65, 67, 70, 72, 74, 76, 77, 79, and 81 of the light chain defined by the Kabat method. Among these amino acid residues, at least three amino acid residues set as charged amino acid residues preferably contain at least one selected from the 3, 5, 9, 17, 18, 20, 22, 60, 74, 76, 77, 79, and 81 amino acid residues of the light chain defined by the Kabat method. More preferably, at least three of the charged amino acid residues contain at least three selected from the 3, 5, 9, 17, 18, 20, 22, 60, 74, 76, 77, 79, and 81 amino acid residues of the light chain defined by the Kabat method.
[0084] When the amino acid residues of FR1 of the light chain of the unmodified antibody are changed, the at least three amino acid residues set as the charged amino acid residues are preferably selected from the 3rd, 5th, 9th, 17th, 18th, 20th and 22nd amino acid residues of the light chain defined by the Kabat method. Examples of such three amino acid residues include any combination of the following (1) to (4).
[0085] (1) amino acid residues 3, 5, and 9 of the light chain as defined by the Kabat method;
[0086] (2) amino acid residues 17, 18, and 20 of the light chain as defined by the Kabat method;
[0087] (3) amino acid residues 18, 20, and 22 of the light chain as defined by the Kabat method; and
[0088] (4) Amino acid residues 5, 9 and 22 of the light chain as defined by the Kabat method.
[0089] When the amino acid residues of FR3 of the light chain of the unmodified antibody are changed, at least three amino acid residues set as charged amino acid residues are preferably selected from the 60th, 63rd, 65th, 67th, 70th, 72nd, 74th, 76th, 77th, 79th and 81st amino acid residues of the light chain defined by the Kabat method. Among these amino acid residues, at least three amino acid residues set as charged amino acid residues preferably contain at least one selected from the 60th, 74th, 76th, 77th, 79th and 81st amino acid residues of the light chain defined by the Kabat method. More preferably, at least three of the charged amino acid residues contain at least three selected from the 60th, 74th, 76th, 77th, 79th and 81st amino acid residues of the light chain defined by the Kabat method. As such three amino acid residues, for example, a combination of any one of the following (5) to (8) can be cited.
[0090] (5) amino acid residues 60, 76, and 77 of the light chain as defined by the Kabat method;
[0091] (6) amino acid residues 74, 76, and 77 of the light chain as defined by the Kabat method;
[0092] (7) amino acid residues 77, 79, and 81 of the light chain as defined by the Kabat method; and
[0093] (8) Amino acid residues 76, 77 and 81 of the light chain as defined by the Kabat method.
[0094] The method of setting the amino acid residue satisfying the above-mentioned conditions of (1) and (2) as a charged amino acid residue can include substitution and insertion of amino acid residues. In the change by insertion of amino acid residues, a charged amino acid residue is inserted between the amino acid residue satisfying the above-mentioned conditions of (1) and (2) and the amino acid residue adjacent to the N-terminal side of the amino acid residue. For example, by inserting a charged amino acid residue between the amino acid residue of L2 and the amino acid residue of L3 of the unchanged antibody, the amino acid residue of L3 can be set as a charged amino acid. In a preferred embodiment, the amino acid residue satisfying the above-mentioned conditions of (1) and (2) is substituted with a charged amino acid residue.
[0095] In this embodiment, the amino acid residues of the FR of the unmodified antibody can be set to charged amino acid residues by known methods such as DNA recombination technology and other molecular biological techniques. For example, when there is a hybridoma that produces unmodified antibodies, RNA extracted from the hybridoma is used to synthesize polynucleotides encoding light chains by reverse transcription reaction and RACE (Rapid Amplification of cDNA ends) method. By using primers for changing at least 3 amino acid residues of FR to amplify this polynucleotide by PCR method, a polynucleotide encoding a light chain that changes FR is obtained. The obtained polynucleotide is integrated into an expression vector known in the prior art to obtain an expression vector containing a polynucleotide encoding a changed antibody. The type of expression vector is not particularly limited, and it can be an expression vector for mammalian cells or an expression vector for Escherichia coli. By transforming or transfecting the expression vector obtained to a suitable host cell (e.g., a mammalian cell or Escherichia coli), an antibody with improved affinity can be obtained.
[0096] When obtaining a modified antibody as a single-chain antibody (scFv), as shown in, for example, WO2013 / 084371, RNA extracted from the above-mentioned hybridoma is used to synthesize a polynucleotide encoding the light chain variable region by reverse transcription reaction and PCR. This polynucleotide is connected by overlap extension PCR method and the like to obtain a polynucleotide encoding an unchanged scFv. By using a primer for changing at least 3 amino acid residues of FR to amplify the polynucleotide obtained by PCR method, a polynucleotide encoding a scFv in which FR is changed is obtained. The obtained polynucleotide is integrated into an expression vector known in the prior art to obtain an expression vector containing a polynucleotide encoding a modified antibody in the form of scFv. By transforming or transfecting the expression vector obtained to an appropriate host cell, a modified antibody in the form of scFv can be obtained.
[0097] When there is no hybridoma producing an unmodified antibody, a hybridoma producing an antibody may be prepared by a known method such as the method described in Kohler and Milstein, Nature, vol. 256, p. 495-497, 1975. Alternatively, RNA obtained from the spleen of an animal such as a mouse immunized with a target antigen may be used. When RNA obtained from the spleen is used, a polynucleotide encoding an unmodified scFv having a desired affinity may be selected from the polynucleotides encoding the unmodified scFv obtained by phage display method or the like, as shown in, for example, Fukunaga A and Tsumoto K, Protein Eng. Des. Sel. 2013, vol. 26, pp. 773-780.
[0098] [2. Antibodies with improved affinity and methods for producing the same]
[0099] The antibody of the present embodiment having an improved affinity for an antigen compared to an unmodified antibody (hereinafter also referred to as an "antibody with improved affinity") is characterized in that at least three of the amino acid residues at positions where the total value of the amino acid frequencies of R, S, T, V, D, and E in the amino acid sequence of the FR of the light chain of the unmodified antibody is 35% or more and the surface area ratio exposed to the solvent is 20% or more are set as charged amino acid residues. This antibody with improved affinity is the same as the "modified antibody" described in the description of the affinity improvement method of the present embodiment.
[0100] The antibody of the present embodiment that affinity is improved is preferably an antibody that the amino acid residue of FR1 and / or FR3 of the light chain of the unmodified antibody is set to a charged amino acid residue. As such an antibody, for example, among the 1st, 3rd, 5th, 7th, 9th, 10th, 12th, 14th, 17th, 18th, 20th, 22th, 60th, 63th, 65th, 67th, 69th, 70th, 72th, 74th, 76th, 77th, 79th and 81st amino acid residues defined by the Kabat method in the unmodified antibody, at least 3 of which are set to charged amino acid residues. In a preferred embodiment, the antibody that affinity is improved is an antibody that at least 3 amino acid residues selected from the 3rd, 5th, 9th, 17th, 18th, 20th, 22th, 60th, 63th, 65th, 67th, 70th, 72th, 74th, 76th, 77th, 79th and 81st amino acid residues defined by the Kabat method in the unmodified antibody are set to charged amino acid residues. In this antibody, the above three amino acid residues more preferably include at least one selected from amino acid residues 3, 5, 9, 17, 18, 20, 22, 60, 74, 76, 77, 79 and 81 of the light chain defined by the Kabat method. The charged amino acid residue is preferably a basic amino acid residue.
[0101] When the affinity-enhanced antibody of the present embodiment is an antibody in which the amino acid residues of FR1 of the light chain of the unmodified antibody are modified, it is preferred that at least three of the amino acid residues 3, 5, 9, 17, 18, 20, and 22 of the light chain defined by the Kabat method in the unmodified antibody are set as charged amino acid residues. As such at least three amino acid residues, for example, a combination of any one of the above (1) to (4) can be cited.
[0102] When the affinity-enhanced antibody of the present embodiment is an antibody in which the amino acid residues of FR1 of the light chain of the unchanged antibody are changed, it is preferred that at least 3 of the 60th, 63rd, 65th, 67th, 70th, 72th, 74th, 76th, 77th, 79th and 81st amino acid residues of the light chain defined by the Kabat method in the unchanged antibody are set as charged amino acid residues. In particular, it is preferred that at least 3 of the 60th, 74th, 76th, 77th, 79th and 81st amino acid residues of the light chain defined by the Kabat method are set as charged amino acid residues. As such at least 3 amino acid residues, for example, a combination of any one of the above-mentioned (5) to (8) can be cited.
[0103] The antibody with improved affinity of the present embodiment can be obtained by the method for producing an antibody with improved affinity for an antigen compared to an unmodified antibody of the present embodiment (hereinafter also referred to as a "production method"). In the production method of the present embodiment, first, in the amino acid sequence of the FR of the light chain of the antibody (unmodified antibody), among the amino acid residues at positions where the total value of the amino acid frequency of R, S, T, V, D and E is 35% or more and the surface area ratio exposed to the solvent is 20% or more, at least 3 are set as charged amino acid residues. The process of changing the amino acid residues in this unmodified antibody is the same as that described for the method for improving affinity of the present embodiment.
[0104] Next, the antibody obtained by the above-mentioned change is recovered. For example, the host cells expressing the antibody with improved affinity are dissolved in a solution containing an appropriate solubilizing agent to free the antibody in the solution. When the above-mentioned host cells secrete the antibody into the culture medium, the culture supernatant is recovered. The free antibody can be recovered by methods known in the prior art such as affinity chromatography. For example, when the manufactured antibody is IgG, it can be recovered by affinity chromatography using protein A or G. It is also possible to purify the recovered antibody by methods known in the prior art such as gel filtration as needed.
[0105] [3. Method for analyzing the amino acid sequence of an antibody]
[0106] The scope of the present invention also includes a method for analyzing the amino acid sequence of an antibody (hereinafter also referred to as an "analysis method"). In the analysis method of the present embodiment, the total value of the amino acid frequency of R, S, T, V, D and E at each position in the amino acid sequence of the FR of the light chain of the antibody and the surface area ratio of each amino acid residue in the amino acid sequence exposed to the solvent are obtained, and the total value of the amino acid frequency at each position and the surface area ratio of each amino acid residue exposed to the solvent are output. The output information is useful for exploring candidates for amino acid residues to be changed, for example, when changing the analyzed antibody. The details of the total value of amino acid frequency and the surface area ratio exposed to the solvent are the same as those described for the affinity improvement method of the present embodiment. The analysis method of the present embodiment can also be used, for example, Figure 1 The analysis system of the amino acid sequence shown was used.
[0107] (Overview of amino acid sequence analysis system)
[0108] Next, an example of an amino acid sequence analysis system is described with reference to the accompanying drawings. However, the present embodiment is not limited to the form shown in this example. Figure 1 The amino acid sequence analysis system includes an amino acid sequence analysis device 10 and a sequence data server 20. The analysis device 10 and the sequence data server 20 are connected via a network 30 such as an intranet or the Internet. Figure 1 In the figure, the analysis device 10 is shown as a general-purpose computer system including a control unit 100 (computer body), an input unit 101, and a display unit 102, but is not limited to this form.
[0109] When the sequence information of the amino acid sequence of the light chain of a plurality of reference antibodies, the three-dimensional structural data of the light chain of the antibody, etc. is requested from the analysis device 10 to the sequence data server 20 via the network 30, their sequence information is downloaded from the sequence data 20 to the analysis device 10. The sequence data server 20 is provided with a database (hereinafter also referred to as "amino acid sequence database") storing information of the amino acid sequence of the light chain of a plurality of reference antibodies, the three-dimensional structural data of the light chain of the antibody, etc. The sequence data server 20 may also be an external data server managed by a third party different from the user using the analysis device 10. As a database (hereinafter also referred to as "external database") that can be used from an external data server, for example, GeneBank, abYsis, IMGT, PDB, BMRB, etc. may be cited.
[0110] exist Figure 11 sequence data server is shown in the figure, but the analysis device 10 can also be connected to multiple sequence data servers. Multiple sequence data servers can also have different types of amino acid sequence databases. For example, a sequence data server has a database related to the amino acid sequence information of proteins containing the amino acid sequences of the light chains of multiple reference antibodies, and another sequence data server can also have a database related to the three-dimensional structure data of proteins containing the light chains of antibodies.
[0111] The analysis device 10 obtains the amino acid sequence of the light chain of the unmodified antibody from the input of the user or the memory medium 40 described later. In addition, the analysis device 10 requests the amino acid sequences of the light chains of a plurality of reference antibodies and the three-dimensional structure data of the light chains of the antibodies from the sequence data server 20 via the network 30. The sequence data server 20 provides the requested data to the analysis device 10 via the network 30. Furthermore, the analysis device 10 uses the obtained sequence to analyze the amino acid sequence of the unmodified antibody.
[0112] (Hardware configuration of amino acid sequence analysis system)
[0113] Reference Figure 2 The control unit 100 of the analysis device 10 includes a CPU (Central Processing Unit) 110, a memory 111, a storage device 112, an interface 113, a reading device 114, and a bus 115 that can connect these in data communication. The control unit 100 is connected to external devices such as the input unit 101 and the output unit 102, and the network 30 in a communication manner through the interface 113. The storage medium 40 is a non-temporary tangible storage medium that can be read by a computer such as a CD-ROM or a USB memory. The sequence data server 20 includes a control unit 210, an input unit 211, an output unit 212, a storage unit 213, and a communication unit 214. In the storage unit 213, an amino acid sequence database 215 is stored. The sequence data server 20 is connected to the network 30 in a communication manner through the communication unit 214. The input units 101 and 211 are input devices such as a mouse and a keyboard. The output units 102 and 212 are display devices such as a liquid crystal display.
[0114] The CPU 110 executes the computer program of the present embodiment stored in the memory 111 or the storage device 112 to perform the processing described below. The memory 111 includes a ROM (Read Only Memory) and a RAM (Random Access Memory). The ROM is composed of, for example, a mask ROM, a PROM, an EPROM, an EEPROM, etc. The ROM records the computer program executed by the CPU 110 and the data used in the execution of the computer program. The RAM is composed of, for example, an SRAM, a DRAM, etc. The RAM is used to read the programs recorded in the ROM and the storage device 112. In addition, the RAM is used as a work area of the CPU 110 when executing these programs.
[0115] The memory device 112 is composed of, for example, a hard disk. In the memory device 112, programs such as an operating system and application programs executed by the CPU 110 and data used in the execution of the programs are stored. As application programs, for example, the computer program of the present embodiment, a program for performing an alignment of amino acid sequences, a program for performing calculation of amino acid frequencies, a program for performing calculation of the surface area ratio exposed to a solvent, etc. can be cited. In addition, in the memory device 112, respective threshold values of amino acid frequencies and surface area ratios exposed to a solvent can also be recorded.
[0116] The reading device 114 is composed of a CD-ROM drive, a DVD-ROM drive, a USB port, an SD card reader, a CF card reader, a memory stick reader, a solid state drive, a floppy disk drive, etc. The reading device 114 can read data recorded in the memory medium 40 (for example, the amino acid sequence of the light chain of the unmodified antibody and / or multiple reference antibodies and / or the information encoding the nucleic acid sequence thereof, etc.) and a computer program.
[0117] (Processing Procedure of Amino Acid Sequence Analysis Device)
[0118] Reference Figure 3 , the analysis process of the amino acid sequence of the antibody performed by the analysis device 10 is described. Among them, the case of outputting the total value of the amino acid frequency of each position and the surface area ratio of each amino acid residue exposed to the solvent using the amino acid sequences of the light chains of multiple reference antibodies downloaded from an external database and the three-dimensional structure data of the light chains of the unchanged antibodies is described as an example. However, the present embodiment is not limited to this example. In the following description, unless otherwise specified, the processing performed by the control unit 100 refers to the processing performed by the CPU 110.
[0119] In step S10, the control unit 100 downloads the data of the amino acid sequence of the light chain of multiple reference antibodies from the amino acid sequence database 215 of the sequence data server 20 via the network 30, and stores it in the memory device 112. The downloaded amino acid sequence can be the sequence of the entire light chain, or it can be the sequence of a part of the light chain containing the amino acid sequence of FR1 and / or FR3. When the user has the data of the amino acid sequence of the light chain of multiple reference antibodies, the control unit 100 can also obtain the data of the amino acid sequence input by the user instead of downloading. The input can be performed by the input unit 101, or by transferring the data of the amino acid sequence stored in the memory medium 40 to the memory device 112.
[0120] In step S11, the control unit 100 compares the amino acid sequences of the light chains of the obtained multiple reference antibodies. Specifically, the control unit 100 aligns the amino acid sequences of the multiple reference antibodies in a manner consistent with the numbering of the amino acid residues in the FR attached by the Kabat method. The comparison can also be performed based on a numbering method other than the Kabat method. In step S12, the control unit 100 calculates the total value of the amino acid frequency of R, S, T, V, D and E at each position of the amino acid sequence of the FR of the multiple reference antibodies. This calculation is the same as that described for the affinity improvement method of this embodiment.
[0121] In step S13, the control unit 100 obtains the amino acid sequence of the light chain of the unmodified antibody. The amino acid sequence of the light chain of the unmodified antibody obtained may be the amino acid sequence of the entire light chain, or may be the amino acid sequence of a portion of the light chain. The amino acid sequence of a portion of the light chain preferably contains the amino acid sequence of FR1 and / or FR3, and more preferably also contains the amino acid sequence of CDR. In a preferred embodiment, the control unit 100 obtains the amino acid sequence of the entire light chain of the unmodified antibody. This amino acid sequence may be input by the user, or may be pre-stored in the memory medium 40 or the memory device 112. When the amino acid sequence of the light chain of the unmodified antibody is in the amino acid sequence database 215, the control unit 100 may also download the data of the amino acid sequence. In step S14, the control unit 100 determines the amino acid residues in the FR of the unmodified antibody at positions corresponding to the positions determined from multiple reference antibodies. The control unit 100 may also compare and determine the amino acid sequence of the light chain of the unmodified antibody and the amino acid sequences of the light chains of multiple reference antibodies. Thus, the control unit 100 acquires the calculated total value of the amino acid frequencies as the total value of the amino acid frequencies at each position of the amino acid sequence of the FR of the unchanged antibody, and stores it in the storage device 112 .
[0122] In step S15, the control unit 100 downloads the three-dimensional structural data of the light chain of the unmodified antibody from the amino acid sequence database 215 based on the amino acid sequence of the light chain of the unmodified antibody. The control unit 100 searches the amino acid sequence of the light chain of the unmodified antibody from the amino acid sequence database 215, and when there is a protein having a sequence consistent with the amino acid sequence of the light chain of the unmodified antibody, the three-dimensional structural data of the protein is downloaded from the database and stored in the storage device 112 as the three-dimensional structural data of the light chain of the unmodified antibody.
[0123] In step S16, the control unit 100 calculates the surface area ratio of each amino acid residue of the FR of the unchanged antibody exposed to the solvent based on the obtained three-dimensional structural data and stores it in the memory device 112. This calculation is the same as that described for the affinity enhancement method of this embodiment. When the user has the three-dimensional structural data of the light chain of the unchanged antibody, the control unit 100 can also obtain the three-dimensional structural data input by the user instead of downloading. The input can be performed by the input unit 101, or by transferring the three-dimensional structural data stored in the memory medium 40 to the memory device 112. When there is no three-dimensional structural data of the light chain of the unchanged antibody in the amino acid sequence database 215, the control unit 100 can also obtain the information necessary for the preparation of the three-dimensional structural data from the database, and prepare the three-dimensional structural data based on the information. Specifically, the control unit 100 retrieves the reference sequence from the amino acid sequence database 215 and downloads the amino acid sequence. Next, the control unit 100 compares the reference sequence with the amino acid sequence of the unchanged antibody. Furthermore, the control unit 100 generates three-dimensional structural data of the unmodified antibody light chain from the known structure of the reference sequence based on the alignment result. The generation of the three-dimensional structural data is the same as that described for the affinity improvement method of this embodiment.
[0124] In step S17, the control unit 100 transmits to the output unit 102 the total value of the amino acid frequency at each position of the amino acid sequence of the FR of the unmodified antibody determined in step S14 and the surface area ratio of each amino acid residue of the FR of the unmodified antibody calculated in step S16 that is exposed to the solvent. Figure 4 An example of a screen showing the analysis results in the output unit 102 is shown. In this screen, the total value of the amino acid frequency at each position (L1 to L23) of the amino acid sequence of FR1 of the unmodified antibody and the surface area ratio exposed to the solvent are shown. However, the display of the screen is not limited to this example.
[0125] exist Figure 3In the process shown in , step S13 may be performed before step S10, S11 or S12. Steps S15 and S16 may be performed before step S10, S11 or S12 as long as they are after the step of obtaining the amino acid sequence of the unmodified antibody (step S13). Steps S10 and S15 may be performed simultaneously as long as they are after the step of obtaining the amino acid sequence of the unmodified antibody (step S13).
[0126] [4. Method for Identifying Candidates for Altered Antibody Positions]
[0127] The scope of the present invention also includes a method for determining candidate positions for antibody modification (hereinafter also referred to as a "specific method"). In the specific method of the present embodiment, the total value of the amino acid frequency of R, S, T, V, D and E at each position in the amino acid sequence of the FR of the light chain of the antibody and the surface area ratio of each amino acid residue in the amino acid sequence exposed to the solvent are obtained, and the amino acid residue at the position where the total value of the amino acid frequency is 35% or more and the surface area ratio exposed to the solvent is 20% or more is determined as a candidate for the position to be modified for the improvement of affinity. The details of the total value of the amino acid frequency and the surface area ratio exposed to the solvent are the same as those described for the affinity improvement method of the present embodiment.
[0128] In the amino acid sequence of the light chain of the antibody, by setting at least 3 of the amino acid residues determined by the specific method of the present embodiment as charged amino acid residues, the affinity of the antibody for the antigen can be improved compared to the unmodified antibody. Furthermore, by recovering the antibody with the modified amino acid residues, a modified antibody with improved affinity for the antigen can be obtained. The modification of the amino acid residues and the recovery of the antibody are the same as those described for the affinity enhancement method of the present embodiment and the manufacturing method of the present embodiment.
[0129] The specific method of this embodiment can be similar to the analytical method of this embodiment, by Figure 1 The amino acid sequence analysis system shown is implemented. The outline and hardware configuration of the amino acid sequence analysis system for implementing the specific method of the present embodiment are the same as those described for the analysis method of the present embodiment.
[0130] (Processing Procedure of Amino Acid Sequence Analysis Device)
[0131] Reference Figure 5, the analysis process of the candidate amino acid sequence for determining the modified position of the antibody performed by the analysis device 10 is described. Among them, the case of calculating the total value of the amino acid frequency at each position and the surface area ratio of each amino acid residue exposed to the solvent using the amino acid sequences of the light chains of multiple reference antibodies downloaded from an external database and the three-dimensional structure data of the light chains of the unchanged antibodies is described as an example. However, the present embodiment is not limited to this example. In the following description, unless otherwise specified, the processing performed by the control unit 100 refers to the processing performed by the CPU 110. Steps S20 to S26 are the same as those described for steps S10 to S16.
[0132] In step S27, the control unit 100 determines an amino acid residue at a position where the total value of the amino acid frequencies of R, S, T, V, D, and E is 35% or more among the positions of the amino acid sequence of the FR of the unmodified antibody determined in step S24, and the surface area ratio exposed to the solvent calculated in step S26 is 20% or more. Furthermore, in step S28, the control unit 100 sends the amino acid residue determined in step S27 to the output unit 102. Figure 6 An example of a screen showing the analysis results displayed in the output unit 102 is shown. In this screen, the total value of the amino acid frequency at each position (L1 to L23) of the amino acid sequence of FR1 of the light chain of the unchanged antibody and the surface area ratio exposed to the solvent are displayed. In this screen, the positions and values of the amino acid residues determined in step S27 are highlighted in bold and marked. However, the display of the screen is not limited to this example. The determined amino acid residues are presented to the user as candidates for the changed positions in the unchanged antibody.
[0133] Reference Figure 7 , the analysis process of the amino acid sequence performed by the analysis device 10 for preparing a sequence when the candidate for the changed position of the antibody is set to a charged amino acid residue is described. Among them, the case of calculating the total value of the amino acid frequency at each position and the surface area ratio of each amino acid residue exposed to the solvent using the amino acid sequences of the light chains of multiple reference antibodies downloaded from an external database and the three-dimensional structure data of the light chains of the unchanged antibodies is described as an example. However, the present embodiment is not limited to this example. In the following description, unless otherwise specified, the processing performed by the control unit 100 refers to the processing performed by the CPU 110. Steps S30 to S36 are the same as those described for steps S10 to S16, and step S37 is the same as step S27.
[0134] In step S38, the control unit 100 generates an amino acid sequence and / or a base sequence encoding the sequence when at least three of the amino acid residues determined in step S37 are set as charged amino acid residues. When generating the amino acid sequence, the control unit 100 generates an amino acid sequence (amino acid sequence of the light chain of the changed antibody) in which at least three of the amino acid residues determined in step S37 are set as R, K, D or E in the amino acid sequence of the light chain of the unmodified antibody obtained in step S33 and stores it in the memory device 112. Which amino acid residue is set as a charged amino acid residue can be preset or determined by the user. As a charged amino acid residue, which one is selected among R, K, D and E can be preset or determined by the user.
[0135] When preparing the base sequence encoding the amino acid sequence of the light chain of the modified antibody, the control unit 100 prepares an amino acid sequence in which at least three of the amino acid residues determined in step S37 are set to R, K, D or E in the amino acid sequence obtained in step S33, converts it into a base sequence and stores it in the memory device 112. When there are multiple codons for one amino acid, which codon to select can be preset or determined by the user. When preparing the base sequence, the control unit 100 can also obtain the base sequence encoding the light chain of the unchanged antibody in step S33. When obtaining the base sequence, the control unit 100 can also prepare the base sequence encoding the amino acid sequence of the light chain of the modified antibody by setting the codon corresponding to the amino acid residue determined in step S37 to the codon corresponding to the charged amino acid residue. Furthermore, in step S39, the control unit 100 sends the amino acid residue determined in step S37 and the amino acid sequence of the light chain of the modified antibody prepared in step S38 and / or the base sequence encoding it to the output unit 102.
[0136] In the specific method of the present embodiment, the electrical properties of the CDR based on the amino acid sequence of the CDR of the unmodified antibody can also be calculated and output. The electrical properties of the CDR are the same as those described for the affinity enhancement method of the present embodiment. In addition, when the calculated electrical properties of the CDR are neutral, among the amino acid residues determined as candidates for the changed positions, a changed amino acid sequence can also be made and output when at least 3 are set as charged amino acid residues (preferably basic amino acid residues).
[0137] Reference Figure 8, the analysis process of the amino acid sequence performed by the analysis device 10 for preparing a sequence when the candidate for the change position of the antibody is set to a basic amino acid residue when the electrical properties of the CDR are neutral is described. Among them, the case of calculating the total value of the amino acid frequency at each position and the surface area ratio of each amino acid residue exposed to the solvent using the amino acid sequences of the light chains of multiple reference antibodies downloaded from an external database and the three-dimensional structure data of the light chains of the unchanged antibodies is described as an example. However, the present embodiment is not limited to this example. In the following description, unless otherwise specified, the processing performed by the control unit 100 refers to the processing performed by the CPU 110. Steps S40 to S46 are the same as those described for steps S10 to S16, and step S47 is the same as step S27.
[0138] In step S48, the control unit 100 calculates the electrical properties of the CDR of the unchanged antibody based on the amino acid sequence of the light chain of the unchanged antibody obtained in step S43. The electrical properties of the CDR are calculated by the above-mentioned formula (III). In step S49, it is determined whether the calculated electrical properties of the CDR are neutral or not. When the value calculated by the above-mentioned formula (III) is -1, 0 or 1, the electrical properties of the CDR are determined to be neutral, and the processing proceeds to step S50. In step S50, the control unit 100 prepares an amino acid sequence and / or a base sequence encoding the sequence when at least 3 of the amino acid residues determined in step S47 are set as basic amino acid residues. Furthermore, in step S51, the control unit 100 sends the amino acid residues determined in step S47, the electrical properties of the CDR calculated in step S48, and the amino acid sequence of the light chain of the modified antibody prepared in step S50 and / or the base sequence encoding it to the output unit 102. In step S49, when the value calculated by the above formula (III) is less than -2 or greater than 2, the electrical properties of the CDR are determined to be not neutral, and the process proceeds to step S52. In step S52, the control unit 100 sends the amino acid residue determined in step S47 and the electrical properties of the CDR calculated in step S48 to the output unit 102.
[0139] Next, the present invention will be described in detail by way of examples, but the present invention is not limited to these examples.
[0140] [Example]
[0141] [Example 1: Preparation of antibodies with altered amino acid residues in FR1 or FR3 of the light chain]
[0142] Variants of the anti-lysozyme antibodies were prepared by substituting three amino acid residues in FR1 or FR3 of the anti-lysozyme antibodies with charged amino acid residues.
[0143] (1) Obtaining the gene of wild-type anti-lysozyme antibody
[0144] The synthesis of the anti-lysozyme antibody gene was outsourced to GenScript Japan Co., Ltd., and a plasmid DNA containing the wild-type anti-lysozyme antibody gene was obtained.
[0145] (2) Preparation of anti-lysozyme antibody variants
[0146] [Reagents]
[0147] QIAprep Spin Miniprep Kit (QIAGEN)
[0148] PrimeSTAR (registered trademark) Max DNA Polymerase (Takara Bio Co., Ltd.)
[0149] Ligation high ver.2 (Toyobo Co., Ltd.)
[0150] T4 Polynucleotide Kinase (Toyobo Co., Ltd.)
[0151] Dpn I (Toyobo Co., Ltd.)
[0152] Competent high DH5α (Toyobo Co., Ltd.)
[0153] (2.1) Primer design and PCR
[0154] In order to replace the specified three amino acid residues of the light chain FR1 or FR3 of the wild-type anti-lysozyme antibody with arginine residues, PCR was performed using the plasmid obtained in (1) above and the primers represented by the following base sequence. In addition, the three numbers recorded in the name of each primer indicate the positions of the amino acid residues substituted by arginine residues in the FR of the light chain defined by the Kabat method. The primers of SEQ ID NOs: 1 to 11 were used as forward primers, and the primers of SEQ ID NOs: 12 to 22 were used as reverse primers.
[0155] [Primers for variant production]
[0156] 2, 4, 6 variant FOR: 5'AGAACCAGAA GCCCGGCGAC CCTCTCGGTC ACCCCCGGC 3' (SEQ IDNO: 1)
[0157] 2, 4, 8 variant FOR: 5'AGAGCAGAGC GACCCTTCG GTCACCCCCG GC 3' (SEQ ID NO: 2)
[0158] 3, 5, 9 variants FOR: 5'GCCCGCGCAC CCTCTCGGTC ACCCCCGGC 3' (SEQ ID NO: 3)
[0159] 4, 8, 13 variants FOR: 5'CCCTCTCGAG AACCCCCGGC AACTCGGTGT CGC 3' (SEQ ID NO: 4)
[0160] 5, 9, 22 variant FOR: 5'GGCAACTCGG TGTCGCTCCG CTGCCGCGCC TCGCAGTCG 3' (SEQ IDNO: 5)
[0161] 13, 16, 19 variant FOR: 5'AACTCGCGAT CGCTCTCGTG CCGCGCCTCG CAGTCG 3' (SEQ IDNO: 6)
[0162] 16, 21, 23 variant FOR: 5'GTGTCGCGAT CGCGACGCGC CTCGCAGTCG ATCGGC 3' (SEQ IDNO: 7)
[0163] 17, 18, 20 variants FOR: 5'CTCTCGTGCC GCGCCTCGCA G 3' (SEQ ID NO: 8)
[0164] 18, 20, 22 variants FOR: 5'CGCTGCCGCG CCTCGCAGTC GATCGGC 3' (SEQ ID NO: 9)
[0165] 19, 21, 23 variants FOR: 5'AGATCGAGAC GCGCCTCGCA GTCGATCGGC 3' (SEQ ID NO: 10)
[0166] 63, 65, 67 variants FOR: 5'GGCACCGACT TCACCCTGTC G 3' (SEQ ID NO: 11)
[0167] 2, 4, 6 variants REV: 5'GACTCTATCT CCTCTGGACA TTATGACTGA GGC 3' (SEQ ID NO: 12)
[0168] 2, 4, 8 variant REV: 5'GGGTTCTGAC TCTATCTCCT CTGGACATTA TGACTGAGGC 3' (SEQ IDNO: 13)
[0169] 3, 5, 9 variant REV: 5'TCTGGCGCAG GCGGATATCT CCTCTGGACA TTATG 3' (SEQ ID NO: 14)
[0170] 4, 8, 13 variant REV: 5'TCGCTCTGCT CTGGGTTCTG ACGATATCTC CTCTGGACAT TATG 3' (SEQ ID NO: 15)
[0171] 5, 9, 22 variant REV: 5'GGGGTGACC GAGAGGGTGC GCGGGCTCTG GCGCAGGACGATATCTCCTC TGG 3' (SEQ ID NO: 16)
[0172] 13, 16, 19 variant REV: 5'TCGGGGGGTT CGCGAGAGGG TCGCCGGGCT CTGGG 3' (SEQ IDNO: 17)
[0173] 16, 21, 23 variant REV: 5'CGAGTTTCGG GGGGTGACCG AGAGGGTCGC 3' (SEQ ID NO: 18)
[0174] 17, 18, 20 variant REV: 5'GCGCACGCGG CGGCCGGGGG TGACCGAGAG GG 3' (SEQ ID NO: 19)
[0175] 18, 20, 22 variant REV: 5'GAGGCGCACG CGGTTGCCGG GGGTGACCGA GAGGG 3' (SEQ IDNO: 20)
[0176] 19, 21, 23 variant REV: 5'CGATCTCGAG TTGCCGGGGG TGACCGAGAG GG 3' (SEQ ID NO: 21)
[0177] 63, 65, 67 variant REV: 5'TCTGCCTCTG CCTCTGAAGC GCGACGGGAT CCCCG 3' (SEQ IDNO: 22)
[0178] A PCR reaction solution having the following composition was prepared using the plasmid obtained in (1) above as a template.
[0179] [PCR reaction solution]
[0180] PrimeSTAR(registered trademark)Max DNA Polymerase 12.5μL Forward primer (10 μM) 1μL Reverse primer (10 μM) 1μL Template plasmid (3ng / μL) 1μL Purified water 9.5μL total 25μL
[0181] The PCR reaction solution prepared was added to the PCR reaction under the following reaction conditions.
[0182] [Reaction conditions]
[0183] At 98°C for 10 seconds,
[0184] 30 cycles of 10 seconds at 98°C, 10 seconds at 54°C, and 45 seconds at 72°C, and
[0185] At 72°C for 3 minutes.
[0186] 1 μL of DpnI (10 U / μL) was added to the obtained PCR product (25 μL) to fragment the PCR product. A ligation reaction solution having the following composition was prepared using the DpnI-treated PCR product. The reaction solution was incubated at 16° C. for 1 hour to perform a ligation reaction.
[0187] [Ligation reaction solution]
[0188] DpnI treated PCR products 2μL Ligation high ver.2 5μL T4 polynucleotide kinase 1μL Purified water 7μL total 15μL
[0189] (2.2) Transformation, plasmid extraction and sequence confirmation
[0190] After adding DH5α (30 μL) to the solution after the ligation reaction (3 μL) and standing on ice for 30 minutes, the mixture was heated at 42°C for 45 seconds for heat shock. Again, after standing on ice for 2 minutes, the entire amount was applied to an LB plate containing ampicillin. By incubating the plate at 37°C for 16 hours, a transformant of Escherichia coli was obtained. The single colony on the plate was taken to an LB liquid culture medium containing ampicillin and cultured with shaking at 37°C for 16 hours (250 rpm). From the obtained Escherichia coli, the plasmid was extracted using the QIAprep Spin Miniprep kit. The base sequence of each plasmid obtained was confirmed using the pCDNA3.4 vector primer. Below, these plasmids are used as plasmids for mammalian cell expression.
[0191] (3) Expression in mammalian cells
[0192] [Reagents]
[0193] Expi293 (trademark) cells (Invitrogen)
[0194] Expi293 (trademark) Expression medium (Invitrogen)
[0195] ExpiFectamine (trademark) 293 transfection kit (Invitrogen)
[0196] (3.1) Transfection
[0197] Expi293 cells were cultured at 37°C with shaking (150 rpm) in a 5% CO2 atmosphere to allow proliferation. 30 mL of cell culture (3.0 x 10 6 cells / mL). A DNA solution of the following composition was prepared using a plasmid encoding each variant and a plasmid encoding a wild-type antibody, and the solution was allowed to stand for 5 minutes.
[0198] [DNA solution]
[0199]
[0200]
[0201] A transfection reagent having the following composition was prepared and allowed to stand for 5 minutes.
[0202] ExpiFectamine Reagent 80μL Light chain plasmid solution 1420μL total 1.5mL
[0203] The prepared DNA solution and transfection reagent were mixed and allowed to stand for 20 minutes. The obtained mixed solution (3 mL) was added to the cell culture (30 mL), and cultured with shaking at 37°C for 20 hours (150 rpm) in a 5% CO2 atmosphere. After 20 hours, 150 μL and 1.5 mL of ExpiFectamine (trademark) were added to each culture to transfect enhancers 1 and 2, and cultured with shaking at 37°C for 6 days (150 rpm) in a 5% CO2 atmosphere.
[0204] (3.2) Antibody recovery and purification
[0205] Each cell culture was centrifuged at 3000 rpm for 5 minutes to recover the culture supernatant. The culture supernatant contains each antibody secreted from the transfected Expi293 (trademark) cells. The obtained culture supernatant was centrifuged again at 15000×G for 10 minutes to recover the supernatant. 100 μL of antibody purification carrier Ni Sepharose HighPerformance (GE Healthcare) was added to the obtained supernatant (30 mL) and reacted at room temperature for 2 hours. The carrier was recovered and the supernatant was removed, and TBS (1 mL) was added to wash the carrier. 1000 μL of TBS containing 100 mM imidazole was added to the carrier to dissolve the antibodies captured by the carrier. This dissolution operation was performed a total of 3 times to obtain an antibody solution.
[0206] (4) Determination of affinity
[0207] The affinity of the prepared variants was measured using Biacore (registered trademark) T200 (GE Healthcare). As the antigen for the anti-lysozyme antibody, lysozyme derived from chicken egg white (Sigma-Aldrich) was used. The antigen was immobilized on the Biacore (registered trademark) sensor chip Series S Sensor Chip CM5 (GE Healthcare) (immobilization: 50RU). The antibody solution was diluted to prepare 30nM, 15nM, 7.5nM, 3.75nM and 1875nM antibody solutions. Antibody solutions of various concentrations (association time 120 seconds and dissociation time 1800 seconds) were transported to Biacore (registered trademark) T200 (GE Healthcare). The measurement data was analyzed using Biacore (registered trademark) Evaluation software to obtain affinity-related data for each antibody. The K of each antibody d The values are shown in Table 2.
[0208]
Table 2
[0209] Anti-lysozyme antibody <![CDATA[K d (M)]]> wild type 1.31E-10 63, 65, 67 variants 9.20E-11 18, 20, 22 variants 6.52E-11 3, 5, 9 variants 7.23E-11 17, 18, 20 variants 1.05E-10 5, 9, 22 variants 6.90E-11
[0210] (5) Results
[0211] As shown in Table 2, the K values of the 63, 65, and 67 variants of the light chain FR3, the 18, 20, and 22 variants, the 3, 5, and 9 variants, the 17, 18, and 20 variants, the 18, 20, and 22 variants, and the 5, 9, and 22 variants of the light chain FR1 were changed. d The K value of wild-type anti-lysozyme antibody d Therefore, the variants shown in Table 2 have improved affinity for antigens compared to the wild type by making the three amino acid residues of FR3 or FR1 basic amino acid residues.
[0212] On the other hand, for the variants not shown in Table 2, no antibody expression was confirmed. The eluate obtained in (3.2) was analyzed by SDS-PAGE and CBB staining to confirm expression. The results are shown in Fig. 9 . As from Fig. 9 It was found that the heavy chain and light chain bands of the antibody were observed in lanes 1 and 2. Thus, the expression of the wild-type antibody and the 63, 65, and 67 variants was confirmed. However, since no antibody bands were observed in lanes 3 to 8, the expression of the 2, 4, and 6 variants, the 2, 4, and 8 variants, the 4, 8, and 13 variants, the 19, 21, and 23 variants, the 13, 16, and 19 variants, and the 16, 21, and 23 variants was not confirmed.
[0213] [Example 2: Characteristics of Antibodies with Improved Affinity for Antigens]
[0214] In order to find the common features of the variants of Example 1 with improved affinity for antigens, the inventors calculated the amino acid frequencies at each position of FR1 and FR3 of the light chain. In addition, the inventors believed that the side chains of the amino acid residues were related to the improvement of the affinity of the antibody molecule surface with the antigen, and calculated the surface area ratio of each amino acid residue of FR1 and FR3 of the light chain exposed to the solvent.
[0215] (1) Amino acid frequency
[0216] The amino acid sequences of the light chains of about 30,000 mouse antibodies were downloaded as reference antibodies from abYsis, a public database that provides the amino acid sequences of antibodies. The amino acid sequences of the light chains of the reference antibodies obtained were aligned in a manner consistent with the numbering of the amino acid residues in the FR of the light chain attached by the Kabat method. The amino acid frequencies of each position of FR1 and FR3 of the light chain of the reference antibody obtained were obtained. The alignment of the sequences and the amino acid frequencies were obtained by abYsis. It was found that at the positions corresponding to the amino acid residues changed by the variant of Example 1, which increased the affinity for the antigen, there was a tendency for the occurrence frequencies of R, S, T, V, D and E to be high. Thus, at each position of FR1 and FR3 of the light chain, the total value of these amino acid frequencies was calculated. The total value of the amino acid frequency was calculated by the above-mentioned formula (I). Among them, the numbering of the FR of the light chain of the reference antibody obtained by the Kabat method is the same as that of the FR of the light chain of the wild-type anti-lysozyme antibody. Therefore, the total value of the amino acid frequency obtained from the amino acid sequence of the light chain of the reference antibody is used as the value for the amino acid sequence of the light chain of the wild-type anti-lysozyme antibody.
[0217] (2) Surface area ratio exposed to solvent
[0218] The amino acid sequence of the light chain of the wild-type anti-lysozyme antibody was retrieved from the PDB, a public database providing three-dimensional structural data of proteins, and the three-dimensional structural data of the light chain of the antibody was downloaded. Using the obtained three-dimensional structural data, the surface area ratio of each amino acid residue of FR1 and FR3 of the light chain of the wild-type anti-lysozyme antibody exposed to the solvent was obtained by Discovery Studio Client v17.2.0.16349. Furthermore, in Discovery Studio Client v17.2.0.16349, the surface area ratio exposed to the solvent was calculated by the above formula (II).
[0219] (3) Results
[0220] Tables 3, 4A and B show the frequencies of the amino acids R, S, T, V, D and E at each position of FR1 and FR3 of the light chain of the wild-type anti-lysozyme antibody and their total values, and the surface area ratio of each amino acid residue exposed to the solvent.
[0221]
Table 3
[0222]
[0223]
[0224]
Table 4A
[0225]
[0226]
Table 4B
[0227]
[0228]
[0229] From these tables, it was found that, as a common feature with the variants of Example 1 having improved affinity for antigens, three of the amino acid residues satisfying both conditions (a) and (b) below in the amino acid sequence of the FR of the antibody light chain were set as charged amino acid residues. In addition, it was found that the amino acid residues altered by the variants whose expression could not be confirmed in Example 1 did not satisfy the conditions (a) and / or (b) below.
[0230] (a) In the amino acid sequence of FR of the antibody light chain, it is at a position where the total value of the amino acid frequency of arginine, serine, threonine, valine, aspartic acid and glutamic acid is 35% or more.
[0231] (b) In the amino acid sequence of FR of the antibody light chain, the surface area ratio exposed to the solvent is 20% or more.
[0232] [Example 3: Preparation of an antibody with altered amino acid residues in FR3 of the light chain]
[0233] It was verified whether the affinity of the antibody for the antigen can be improved by replacing three of the amino acid residues satisfying both conditions (a) and (b) found in Example 2 with charged amino acid residues. Specifically, variants of the anti-lysozyme antibody different from the variant prepared in Example 1 were prepared, and their affinity for the antigen was measured.
[0234] (1) Preparation of anti-lysozyme antibody variants
[0235] Three amino acid residues to be changed in the light chain FR3 of the wild-type anti-lysozyme antibody were selected from Tables 4A and B. In order to replace the selected three designated amino acid residues with arginine residues, PCR was performed in the same manner as in Example 1 using the primers shown in the following base sequences. Primers of SEQ ID NOs: 23 to 28 were used as forward primers, and primers of SEQ ID NOs: 29 to 34 were used as reverse primers.
[0236] [Primers for variant production]
[0237] 60, 63, 65 variants FOR: 5'GAGGCTCGGG CACCGACTTC ACCCTGTC 3' (SEQ ID NO: 23)
[0238] 60, 76, 77 variant FOR: 5'TCGGGCACCG ACTTCACCCT GTCGATCAGA AGAGTCGAGACGGAGGAC 3' (SEQ ID NO: 24)
[0239] 65, 67, 70 variants FOR: 5'CCAGATTCAC CCTGTCGATC AACAGCGTCG AG 3' (SEQ ID NO: 25)
[0240] 67, 70, 72 variants FOR: 5'CCAGATTCAG ACTGTCGATC AACAGCGTCG AGAC 3' (SEQ ID NO: 26)
[0241] 74, 76, 77 variants FOR: 5'AGTCGAGACG GAGGACTTCG G 3' (SEQ ID NO: 27)
[0242] 77, 79, 81 variant FOR: 5'AGAACGAGAG ACTTCGGCAT GTACTTCTGC 3' (SEQ ID NO: 28)
[0243] 60, 63, 65 variant REV: 5'TGCCTCTGAA GCGTCTCGGG ATCCCCGAGA TC 3' (SEQ ID NO: 29)
[0244] 60, 76, 77 variant REV: 5'GCCCGAGCCG CTGAAGCGTC TCGGGATCCC CGAGATC 3' (SEQ IDNO: 30)
[0245] 65, 67, 70 variant REV: 5'TGCCTCTGCC TCTGCCGCTG AAGC 3' (SEQ ID NO: 31)
[0246] 67, 70, 72 variant REV: 5'TGCCTCTGCC CGAGCCGCTG AAG 3' (SEQ ID NO: 32)
[0247] 74, 76, 77 variant REV: 5'CTTCTGATTC TCAGGGTGAA GTCG 3' (SEQ ID NO: 33)
[0248] 77, 79, 81 variant REV: 5'GACTCTGTTG ATCGACAGGG TGAAGTCG 3' (SEQ ID NO: 34)
[0249] Using the obtained PCR products, plasmids containing genes encoding variant light chains and plasmids containing genes encoding wild-type heavy chains were obtained in the same manner as in Example 1. Using these plasmids, each antibody was expressed in Expi293 (trademark) cells in the same manner as in Example 1, and the obtained culture supernatant was purified to obtain solutions of variant anti-lysozyme antibodies.
[0250] (2) Determination of affinity
[0251] The affinity of the prepared variants was measured using Bia core (registered trademark) T200 (GE Healthcare) in the same manner as in Example 1. Table 5 shows the results.
[0252]
Table 5
[0253] Anti-lysozyme antibody <![CDATA[K d (M) <!-- 22 -->]]> wild type 1.3E-10 60, 63, 65 variants 6.6E-11 67, 70, 72 variants 1.4E-11 74, 76, 77 variants 5.6E-11 77, 79, 81 variants 1.0E-10 65, 67, 70 variants 2.0E-11 60, 76, 77 variants 9.7E-11
[0254] As shown in Table 5, the K d The K values of wild-type anti-lysozyme antibody were d This suggests that the affinity of the antibody for the antigen can be improved by substituting three of the amino acid residues satisfying both conditions (a) and (b) found in Example 2 with arginine residues.
[0255] [Example 4: Preparation of antibodies with altered amino acid residues in FR1 or FR3 of the light chain (2)]
[0256] As unmodified antibodies, mouse anti-lysozyme antibody (Hy-HE L5) of a different clone from the anti-lysozyme antibody of Example 1, mouse anti-thyroid stimulating hormone (TSH) antibody, and humanized anti-HER2 antibody (trastuzumab) were used. It was verified whether the affinity of the antibody for the antigen could be improved by replacing three of the amino acid residues satisfying both the above conditions (a) and (b) in FR1 or FR3 of the light chain of these antibodies with charged amino acid residues.
[0257] (1) Production of variants
[0258] (1.1) Acquisition of a gene encoding the light chain of a variant of an anti-lysozyme antibody (Hy-HE L5)
[0259] As amino acid residues satisfying both conditions (a) and (b) above, amino acid residues 3, 5, and 9 of light chain FR1 were selected from Table 3. In order to replace these amino acid residues with histidine residues, PCR was performed in the same manner as in Example 1 using primers represented by the following base sequences. Primer SEQ ID NO: 46 was used as a forward primer, and primer SEQ ID NO: 47 was used as a reverse primer.
[0260] 3, 5, 9 variants (His) FOR: 5' CATCTGCACC AATCACCGCA CATTATGTCC GCATCTC 3' (SEQID NO: 46)
[0261] 3, 5, 9 variant (His) REV: 5'TATGTCCCCT CTGCTCATAA TCACAGAGGC ACTG 3' (S EQ IDNO: 47)
[0262] (1.2) Acquisition of a gene encoding the light chain of an anti-TSH antibody variant
[0263] As the total value of the amino acid frequencies of R, S, T, V, D and E at each position of the amino acid sequence of the light chain FR of the wild-type anti-TSH antibody, the total value of the amino acid frequencies recorded in Table 3 was used. The surface area ratio of each amino acid residue of the light chain FR of the anti-TSH antibody exposed to the solvent was obtained based on the three-dimensional structure data of the light chain of the wild-type anti-TSH antibody downloaded from the database PDB in the same manner as in Example 2. As amino acid residues that satisfy both the conditions (a) and (b) above, the 18th, 20th and 22nd amino acid residues of the light chain FR1 were selected. In order to replace these amino acid residues with lysine residues, PCR was performed in the same manner as in Example 1 using the primers shown in the following base sequence. The primer of SEQ ID NO: 48 was used as a forward primer, and the primer of SEQ ID NO: 49 was used as a reverse primer.
[0264] 18, 20, 22 variant (Lys)FOR: 5'AAGGCCAAGA TTAAGTGCAG ATCTAATCAG AGCGTTG3' (SEQID NO: 48)
[0265] 18, 20, 22 variants (Lys) REV: 5'ATCTCCAAGA CTGACAGGCA GGGAGAGTG 3' (SEQ ID NO: 49)
[0266] (1.3) Acquisition of genes encoding light chains of humanized anti-HER2 antibody variants
[0267] The amino acid sequences of the light chains of about 30,000 human antibodies were downloaded from the database abYsis as reference antibodies. As in Example 2, the amino acid sequences of the light chains of the reference antibodies were compared to calculate the total values of the amino acid frequencies of R, S, T, V, D and E at each position of the amino acid sequence of the FR. The surface area ratio of each amino acid residue of the light chain FR of the anti-HER2 antibody exposed to the solvent was obtained based on the three-dimensional structure data of the light chain of the humanized anti-HER2 antibody downloaded from the database PDB as in Example 2. The 76th, 77th and 81st amino acid residues of the light chain FR3 were selected. In order to replace these amino acid residues with arginine residues, PCR was performed in the same manner as in Example 1 using the primers shown in the following base sequence. The primer of SEQ ID NO: 50 was used as the forward primer, and the primer of SEQ ID NO: 51 was used as the reverse primer.
[0268] 76, 77, 81 variant (Arg)FOR: 5'CAGCCGAGAG ACTTCGCCAC GTATTACTG 3' (SEQ ID NO: 50)
[0269] 76, 77, 81 variant (Arg) REV: 5'CAGTCTTCTG ATCGTCAGGG TAAAATCGGT AC 3' (SEQ IDNO: 51)
[0270] (1.4) Acquisition of variants of each antibody
[0271] Using the obtained PCR products, plasmids containing genes encoding light chains of variants of each antibody and plasmids containing genes encoding wild-type heavy chains of each antibody were obtained in the same manner as in Example 1. Using these plasmids, each antibody was expressed in Expi293 (trademark) cells in the same manner as in Example 1, and the obtained culture supernatant was purified to obtain a solution of each antibody variant. The amino acid sequence of the light chain of the 76, 77, 81 variants (Arg) of the humanized anti-HER2 antibody is shown in SEQ ID NO: 52.
[0272] (2) Determination of affinity
[0273] The affinity of the variants prepared using Biacore (registered trademark) T200 (GE Healthcare) was measured in the same manner as in Example 1. In the measurement, TSH protein (R&D Systems) was used as the antigen for the anti-TSH antibody, and HER2 protein (R&D Systems, Catalog No.: 1129-ER) was used as the antigen for the anti-HER2 antibody. The results are shown in Table 6. In the table, "ratio" refers to the ratio of the wild-type K d K of the variant when the value is set to 1 d The ratio of value.
[0274]
Table 6
[0275]
[0276] As shown in Table 6, the Kd values of all variants were lower than the Kd value of the wild-type antibody. This suggests that, for antibodies different from the anti-lysozyme antibody of Example 1, the affinity of the antibody for the antigen can be improved by changing three of the amino acid residues that satisfy both conditions (a) and (b).
[0277]
Explanation of symbols
[0278] 10: Amino acid sequence analysis device
[0279] 20: Sequence Data Server
[0280] 30: Network
[0281] 40: Memory Medium
[0282] 100: Control unit (computer body)
[0283] 101: Input
[0284] 102: Output unit
[0285] 110: CPU
[0286] 111: Memory
[0287] 112: Memory Device
[0288] 113: Interface
[0289] 114: Reading device
[0290] 115: Bus
[0291] 210: Control Department
[0292] 211: Input
[0293] 212: Output
[0294] 213: Memory Department
[0295] 214: Ministry of Communications
[0296] 215: Amino Acid Sequence Database
[0297] This manual also includes the following contents:
[0298] 1. A method for improving the affinity of an antibody for an antigen compared to an unmodified antibody, comprising: in the amino acid sequence of the framework region of the light chain of the antibody, setting at least three of the amino acid residues having the following characteristics as charged amino acid residues:
[0299] Located at a position where the total value of the amino acid frequencies of arginine, serine, threonine, valine, aspartic acid, and glutamic acid is 35% or more, and
[0300] The solvent exposed surface area ratio was 20% or more.
[0301] 2. The method according to embodiment 1, wherein the amino acid residue at the position where the total value of the amino acid frequency is 35% or more is determined by the following step:
[0302] a step of obtaining amino acid sequences of light chains of a plurality of reference antibodies,
[0303] a step of aligning the amino acid sequences of the light chains of the plurality of reference antibodies to calculate the total value of the amino acid frequencies of arginine, serine, threonine, valine, aspartic acid and glutamic acid at each position of the amino acid sequence of the framework region,
[0304] a step of determining a position at which the total value of the acquired amino acid frequencies is 35% or more, and
[0305] The step of determining, in the framework region of the light chain of the unaltered antibody, amino acid residues located at positions corresponding to the positions determined from the plurality of reference antibodies.
[0306] 3. The method of embodiment 1 or 2, wherein the solvent exposed surface area ratio shows that 20% or more of the amino acid residues are determined based on the amino acid sequence of the light chain of the unmodified antibody.
[0307] 4. The method according to any one of embodiments 1 to 3, wherein the amino acid residues showing a solvent exposed surface area ratio of 20% or more are determined by the following steps:
[0308] a step of obtaining three-dimensional structural data of the light chain of the unmodified antibody using the amino acid sequence of the light chain of the unmodified antibody,
[0309] a step of obtaining a solvent exposed surface area ratio of each amino acid residue in the framework region based on the three-dimensional structure data, and
[0310] A step of identifying amino acid residues having a solvent exposed surface area ratio of 20% or more.
[0311] 5. An altered antibody having an improved affinity for an antigen compared to an unaltered antibody, wherein
[0312] In the amino acid sequence of the framework region of the light chain of the unaltered antibody, at least three of the amino acid residues having the following characteristics are set as charged amino acid residues:
[0313] Located at a position where the total value of the amino acid frequencies of arginine, serine, threonine, valine, aspartic acid, and glutamic acid is 35% or more, and
[0314] The solvent exposed surface area ratio was 20% or more.
[0315] 6. A method for producing an antibody having improved affinity for an antigen compared to an unmodified antibody, comprising:
[0316] A step of setting at least three of the amino acid residues having the following characteristics as charged amino acid residues in the amino acid sequence of the light chain framework region of the antibody:
[0317] Located at a position where the total value of the amino acid frequencies of arginine, serine, threonine, valine, aspartic acid, and glutamic acid is 35% or more, and
[0318] The solvent exposed surface area ratio shows 20% or more, and
[0319] A step of recovering the antibody obtained in the above step.
[0320] 7. A method for analyzing the amino acid sequence of an antibody, comprising:
[0321] a step of obtaining a total value of the amino acid frequencies of arginine, serine, threonine, valine, aspartic acid, and glutamic acid at each position in the amino acid sequence of the framework region of the light chain of the antibody,
[0322] a step of obtaining the solvent exposed surface area ratio of each amino acid residue in the framework region of the light chain of the antibody, and
[0323] A step of outputting the acquired total value of the amino acid frequency at each position and the solvent exposed surface area ratio of each amino acid residue.
[0324] 8. The method according to embodiment 7, wherein the total value of the amino acid frequencies of the antibody is obtained by the following step:
[0325] a step of obtaining amino acid sequences of light chains of a plurality of reference antibodies,
[0326] a step of aligning the amino acid sequences of the light chains of the plurality of reference antibodies to calculate the total value of the amino acid frequencies of arginine, serine, threonine, valine, aspartic acid and glutamic acid at each position of the amino acid sequence of the framework region, and
[0327] A step of acquiring the calculated total value of the amino acid frequencies as the total value of the amino acid frequencies at each position of the amino acid sequence of the framework region of the antibody corresponding to each position of the plurality of reference antibodies.
[0328] 9. The method of embodiment 8, wherein the amino acid sequences of the light chains of the plurality of reference antibodies comprise:
[0329] Amino acid sequences downloaded from external databases, and / or
[0330] The amino acid sequence is entered by the user.
[0331] 10. The method according to any one of embodiments 7 to 9, wherein in the step of obtaining the solvent exposed surface area ratio of the antibody, the solvent exposed surface area ratio of the antibody is obtained based on the amino acid sequence of the framework region of the light chain of the antibody.
[0332] 11. The method according to any one of embodiments 7 to 10, further comprising: using the amino acid sequence of the light chain of the antibody, obtaining three-dimensional structural data of the light chain of the antibody,
[0333] In the step of obtaining the solvent exposed surface area ratio of the antibody, the solvent exposed surface area ratio of each amino acid residue in the framework region is obtained based on the three-dimensional structural data.
[0334] 12. The method of embodiment 11, wherein the three-dimensional structural data of the light chain of the antibody comprises at least one selected from the following data:
[0335] Three-dimensional structure data retrieved from an external database using the amino acid sequence of the light chain of the antibody and downloaded from the external database;
[0336] Downloading information necessary for preparing the three-dimensional structural data of the light chain of the antibody from an external database, and preparing the three-dimensional structural data based on the downloaded information; and
[0337] The three-dimensional structure data is input by the user.
[0338] 13. A method for determining candidate altered positions of an antibody, comprising:
[0339] a step of obtaining a total value of the amino acid frequencies of arginine, serine, threonine, valine, aspartic acid, and glutamic acid at each position in the amino acid sequence of the framework region of the light chain of the antibody,
[0340] a step of obtaining the solvent exposed surface area ratio of each amino acid residue in the framework region of the light chain of the antibody, and
[0341] A step of identifying the amino acid residues located at positions where the total value of amino acid frequencies is 35% or more and where the solvent exposed surface area ratio is 20% or more as candidate amino acid residues to be modified in order to improve the affinity of the antibody for the antigen.
[0342] 14. The method described in embodiment 13 also includes: a process of outputting the determined candidate amino acid residues.
[0343] 15. The method described in embodiment 13 or 14, wherein the amino acid sequence of the framework region of the light chain of the antibody is obtained from the amino acid sequence of the light chain of the antibody input by a user.
[0344] 16. The method described in embodiment 15 further includes: a step of preparing a changed amino acid sequence in which at least three of the candidate amino acid residues are set as charged amino acids in the amino acid sequence of the light chain of the antibody input by the user.
[0345] 17. The method described in embodiment 16 also includes: a step of outputting the prepared changed amino acid sequence.
[0346] 18. The method according to any one of embodiments 13 to 17, wherein the amino acid residue at the position where the total value of the amino acid frequency is 35% or more is determined by the following step:
[0347] a step of obtaining amino acid sequences of light chains of a plurality of reference antibodies,
[0348] a step of aligning the amino acid sequences of the light chains of the plurality of reference antibodies to calculate the total value of the amino acid frequencies of arginine, serine, threonine, valine, aspartic acid and glutamic acid at each position of the amino acid sequence of the framework region,
[0349] a step of determining a position at which the total value of the acquired amino acid frequencies is 35% or more, and
[0350] A step of determining, in the framework region of the light chain of the antibody, amino acid residues located at positions corresponding to the positions determined from the plurality of reference antibodies.
[0351] 19. The method of embodiment 18, wherein the amino acid sequences of the light chains of the plurality of reference antibodies comprise:
[0352] Amino acid sequences downloaded from external databases, and / or
[0353] The amino acid sequence input by the user.
[0354] 20. The method according to any one of embodiments 13 to 19, wherein the amino acid residues showing a solvent exposed surface area ratio of 20% or more are determined by the following steps:
[0355] a step of obtaining three-dimensional structural data of the light chain of the antibody using the amino acid sequence of the light chain of the antibody,
[0356] a step of obtaining a solvent exposed surface area ratio of each amino acid residue in the framework region based on the three-dimensional structure data, and
[0357] A step of identifying amino acid residues having a solvent exposed surface area ratio of 20% or more.
[0358] 21. The method of embodiment 20, wherein the three-dimensional structural data of the light chain of the antibody comprises at least one selected from the following data:
[0359] Three-dimensional structure data retrieved from an external database using the amino acid sequence of the light chain of the antibody and downloaded from the external database;
[0360] Downloading information necessary for preparing the three-dimensional structural data of the light chain of the antibody from an external database, and preparing the three-dimensional structural data based on the downloaded information; and
[0361] The three-dimensional structure data is input by the user.
[0362] 22. The method according to any one of embodiments 13 to 21, further comprising: calculating the electrical properties of the complementarity determining region (CDR) from the amino acid sequence of the light chain of the antibody,
[0363] The electrical properties are determined by the following formula (III):
[0364] Z = [the number of basic amino acid residues in the amino acid sequence of CDR] - [the number of acidic amino acid residues in the amino acid sequence of CDR] (III)
[0365] In the above formula,
[0366] When Z is -1, 0 or 1, the electrical properties of the CDR are neutral.
[0367] When Z is 2 or more, the electrical characteristic of CDR is positive charge.
[0368] When Z is -2 or less, the electrical characteristic of CDR is negative charge.
[0369] 23. The method described in embodiment 22 further includes: a step of outputting the calculated electrical characteristics.
[0370] 24. The method described in embodiment 22 or 23, wherein when the calculated electrical properties of the CDR are neutral, a modified amino acid sequence is prepared in which at least three of the candidate amino acid residues are set as basic amino acid residues.
[0371] 25. An altered antibody having an improved affinity for an antigen compared to an unaltered antibody, wherein
[0372] The positions of the amino acid residues to be changed are positions of at least three amino acid residues among the candidate amino acid residues determined by the method according to any one of embodiments 13 to 24,
[0373] The changes are to charged amino acid residues.
[0374] 26. A method for producing an antibody having improved affinity for an antigen compared to an unmodified antibody, comprising:
[0375] a step of setting at least three of the candidate amino acid residues determined by the method according to any one of embodiments 13 to 24 as charged amino acid residues, and
[0376] A step of recovering the antibody obtained in the above step.
[0377] 27. A method for increasing the affinity of an antibody for an antigen, comprising:
[0378] By setting at least three amino acid residues selected from amino acid residues 3, 5, 9, 17, 18, 20, 22, 60, 63, 65, 67, 70, 72, 74, 76, 77, 79 and 81 of the light chain defined by the Kabat method as charged amino acid residues in an unmodified antibody, the affinity for the antigen is increased compared to the unmodified antibody,
[0379] The three amino acid residues include at least one selected from amino acid residues 3, 5, 9, 17, 18, 20, 22, 60, 74, 76, 77, 79 and 81 of the light chain.
[0380] 28. The method described in embodiment 27, wherein the three amino acid residues are selected from amino acid residues 3, 5, 9, 17, 18, 20 and 22 of the light chain.
[0381] 29. An altered antibody having an improved affinity for an antigen compared to an unaltered antibody, wherein
[0382] At least three amino acid residues selected from amino acid residues 3, 5, 9, 17, 18, 20, 22, 60, 63, 65, 67, 70, 72, 74, 76, 77, 79 and 81 of the light chain defined by the Kabat method in the unmodified antibody are set as charged amino acid residues, and
[0383] The three amino acid residues include at least one of the amino acid residues selected from positions 3, 5, 9, 17, 18, 20, 22, 60, 74, 76, 77, 79 and 81 of the light chain.
[0384] 30. A method for producing an antibody having improved affinity for an antigen compared to an unmodified antibody, comprising:
[0385] A step of making at least three amino acid residues selected from amino acid residues 3, 5, 9, 17, 18, 20, 22, 60, 63, 65, 67, 70, 72, 74, 76, 77, 79 and 81 of the light chain defined by the Kabat method as charged amino acid residues in the unmodified antibody, and
[0386] a step of recovering the antibody obtained in the above step,
[0387] The three amino acid residues include at least one selected from amino acid residues 3, 5, 9, 17, 18, 20, 22, 60, 74, 76, 77, 79 and 81 of the light chain.
[0388] 31. The method of any one of embodiments 1 to 4, 6, 16, 26, 27 and 30 or the antibody of any one of embodiments 5, 25 and 29, wherein the charged amino acid residue is a basic amino acid residue.
[0389] 32. The method of any one of embodiments 1 to 4, 6, 16, 24, 26, 27, 30 and 31 or the antibody of any one of embodiments 5, 25, 29 and 31, wherein the framework region is framework region 1 or framework region 3.
Claims
1. A method for increasing the affinity of an antibody for an antigen, comprising: By setting at least three amino acid residues selected from amino acid residues 60, 63, 65, 67, 70, 72, 74, 76, 77, 79 and 81 of the light chain defined by the Kabat method as charged amino acid residues in the unmodified antibody, the affinity for the antigen is improved compared to the unmodified antibody, The three amino acid residues include at least one selected from amino acid residues 74, 76, 77, 79 and 81 of the light chain.
2. A method for producing an antibody having improved affinity for an antigen compared to an unmodified antibody, comprising: A step of modifying, in the unmodified antibody, at least three amino acid residues selected from amino acid residues 60, 63, 65, 67, 70, 72, 74, 76, 77, 79 and 81 of the light chain as defined by the Kabat method as charged amino acid residues, and a step of recovering the antibody obtained in the above step, The three amino acid residues include at least one selected from amino acid residues 74, 76, 77, 79 and 81 of the light chain.
3. The method of claim 1 or 2, wherein the at least three amino acid residues are selected from amino acid residues 60, 74, 76, 77, 79 and 81 of the light chain.
4. The method of claim 1 or 2, wherein the at least three amino acid residues are amino acid residues 60, 76, and 77 of the light chain.
5. The method of claim 1 or 2, wherein the at least three amino acid residues are amino acid residues 74, 76, and 77 of the light chain.
6. The method of claim 1 or 2, wherein the at least three amino acid residues are amino acid residues 77, 79 and 81 of the light chain.
7. An altered antibody having an improved affinity for an antigen compared to an unaltered antibody, wherein At least three amino acid residues selected from amino acid residues 60, 63, 65, 67, 70, 72, 74, 76, 77, 79 and 81 of the light chain defined by the Kabat method in the unaltered antibody are set as charged amino acid residues, and The three amino acid residues include at least one selected from amino acid residues 74, 76, 77, 79 and 81 of the light chain.
8. The altered antibody of claim 7, wherein the at least three amino acid residues are at least three selected from amino acid residues 60, 74, 76, 77, 79 and 81 of the light chain.
9. The altered antibody of claim 7, wherein the at least three amino acid residues are amino acid residues 60, 76, and 77 of the light chain.
10. The altered antibody of claim 7, wherein the at least three amino acid residues are amino acid residues 74, 76, and 77 of the light chain.
11. The altered antibody of claim 7, wherein the at least three amino acid residues are amino acid residues 77, 79, and 81 of the light chain.
12. The method according to claim 1 or 2, or the altered antibody according to claim 7, wherein the charged amino acid residue is a basic amino acid residue.
13. The method according to claim 1 or 2, or the modified antibody according to claim 7, wherein the antibody is in the form of an antibody fragment.
14. The method or altered antibody of claim 13, wherein the antibody fragment is a Fab fragment, a F(ab')2 fragment, a Fab' fragment, a Fv fragment, a dAb fragment, a scFv, or a rIgG.
